A case of severe interstitial lung disease developed during administration of abemaciclib but successfully rescued

DOI IR Open Access
  • Inui Tomohiro
    Department of Thoracic, Endocrine Surgery and Oncology, Tokushima University Graduate School, Tokushima, Japan
  • Inoue Hiroaki
    Department of Thoracic, Endocrine Surgery and Oncology, Tokushima University Graduate School, Tokushima, Japan
  • Isomura Yuta
    Department of Respiratory Medicine and Rheumatology Graduate School of Biomedical Sciences Tokushima University, Tokushima, Japan
  • Yukishige Sawaka
    Department of Thoracic, Endocrine Surgery and Oncology, Tokushima University Graduate School, Tokushima, Japan
  • Miyamoto Naoki
    Department of Thoracic, Endocrine Surgery and Oncology, Tokushima University Graduate School, Tokushima, Japan
  • Sasa Souichirou
    Department of Thoracic, Endocrine Surgery and Oncology, Tokushima University Graduate School, Tokushima, Japan
  • Misaki Mariko
    Department of Thoracic, Endocrine Surgery and Oncology, Tokushima University Graduate School, Tokushima, Japan
  • Goto Masakazu
    Department of Thoracic, Endocrine Surgery and Oncology, Tokushima University Graduate School, Tokushima, Japan
  • Toba Hiroaki
    Department of Thoracic, Endocrine Surgery and Oncology, Tokushima University Graduate School, Tokushima, Japan
  • Takizawa Hiromitsu
    Department of Thoracic, Endocrine Surgery and Oncology, Tokushima University Graduate School, Tokushima, Japan

Bibliographic Information

Other Title
  • アベマシクリブ投与中に重篤な間質性肺疾患をきたしたが救命しえた１例

Search this article

Description

<p>Abemaciclib, Selective cyclin-dependent kinase 4 and 6 inhibitor has become available for use in hormone receptor-positive and HER2-negative unresectable or recurrent breast cancer, significantly extending progression-free survival and improving prognosis.　However, caution is necessary as in some cases it may cause drug-induced interstitial lung disease, occasionally leading to severe exacerbations.　The case involves a 75-year-old female who was emergency transported to our hospital due to dyspnea occurring 11 months after initiating abemaciclib + letrozole therapy for hormone receptor-positive, HER2-negative recurrent breast cancer.　Upon arrival, she presented with type Ⅰ respiratory failure with PCO2 : 24．5 mmHg, PO2 : 61．2 mmHg, and CT revealing ground-glass opacities in both lung fields.　Diagnosed with drug-induced interstitial lung disease, she underwent endotracheal intubation followed by steroid pulse therapy.　After three rounds of steroid pulses, symptoms gradually improved, allowing for discharge home with oxygen supplementation.　Despite the development of severe interstitial lung disease in this case, prompt initiation of treatment facilitated successful life-saving intervention.</p>

Journal

  • SHIKOKU ACTA MEDICA

    SHIKOKU ACTA MEDICA 80 (3.4), 121-124, 2024

    Tokushima Medical Association

Keywords

Details 詳細情報について

Report a problem

Back to top